Related references
Note: Only part of the references are listed.Full central neurokinin-1 receptor blockade is required for efficacy in depression: evidence from orvepitant clinical studies
Emiliangelo Ratti et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2013)
A pharmacokinetic PET study of NK1 receptor occupancy
Stefano Zamuner et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2012)
Results From 2 Randomized, Double-Blind, Placebo-Controlled Studies of the Novel NK1 Receptor Antagonist Casopitant in Patients With Major Depressive Disorder
Emiliangelo Ratti et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2011)
Discovery and Biological Characterization of (2R,4S)-1′-Acetyl-N-{(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-2-(4-fluoro-2-methylphenyl)-N-methyl-4,4′-bipiperidine-1-carboxamide as a New Potent and Selective Neurokinin 1 (NK1) Receptor Antagonist Clinical Candidate
Romano Di Fabio et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
Tachykinin Receptors as Therapeutic Targets in Stress-Related Disorders
Karl Ebner et al.
CURRENT PHARMACEUTICAL DESIGN (2009)
Discovery Process and Pharmacological Characterization of 2-(S)-(4-Fluoro-2-methylphenyl)piperazine-1-carboxylic Acid [1-(R)-(3,5-Bis-trifluoromethylphenyl)ethyl]methylamide (Vestipitant) as a Potent, Selective, and Orally Active NK1 Receptor Antagonist
Romano Di Fabio et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
Neurokinin1 Antagonists Potentiate Antidepressant Properties of Serotonin Reuptake Inhibitors, Yet Blunt Their Anxiogenic Actions: A Neurochemical, Electrophysiological, and Behavioral Characterization
Alain Gobert et al.
NEUROPSYCHOPHARMACOLOGY (2009)
Cellular and behavioural profile of the novel, selective neurokinin1 receptor antagonist, vestipitant:: A comparison to other agents
Mauricette Brocco et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2008)
Neurokinin 1 receptor antagonism promotes active stress coping via enhanced septal 5-HT transmission
Karl Ebner et al.
NEUROPSYCHOPHARMACOLOGY (2008)
Neurokinin 1 receptor antagonism requires norepinephrine to increase serotonin function
Gabriella Gobbi et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2007)
Neurobiology of sleep
Madhu Kalia
METABOLISM-CLINICAL AND EXPERIMENTAL (2006)
Elevated cerebrospinal fluid substance P concentrations in posttraumatic stress disorder and major depression
TD Geracioti et al.
AMERICAN JOURNAL OF PSYCHIATRY (2006)
Lack of efficacy of the substance P (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder
M Keller et al.
BIOLOGICAL PSYCHIATRY (2006)
Effect of neurokinin-1 receptor antagonists on serotoninergic, noradrenergic and hippocampal neurons: Comparison with antidepressant drugs
G Gobbi et al.
PEPTIDES (2005)
Do substance P and the NKI receptor have a role in depression and anxiety?
S McLean
CURRENT PHARMACEUTICAL DESIGN (2005)
Demonstration of the efficacy and safety of a novel substance P (NK1) receptor antagonist in major depression
MS Kramer et al.
NEUROPSYCHOPHARMACOLOGY (2004)
Substance P serum levels are increased in major depression:: Preliminary results
B Bondy et al.
BIOLOGICAL PSYCHIATRY (2003)
Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders
A Holmes et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2003)
Sustained blockade of neurokinin-1 receptors enhances serotonin neurotransmission
N Haddjeri et al.
BIOLOGICAL PSYCHIATRY (2001)
Share Paper
